The pharmacological management of erectile dysfunction – Update 2016
Erectile dysfunction (ED) is a trivial condition with a prevailing incidence worldwide. Phosphodiesterase-5 inhibitors (PDE-5) have revolutionised the treatment of ED and are regarded as one of the most successful drug groups in modern medicine. Generally PDE-5 inhibitors are well tolerated and the...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
AOSIS
2016
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/ac2c0879c48f4050a954caea45b7c80c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Erectile dysfunction (ED) is a trivial condition with a prevailing incidence worldwide. Phosphodiesterase-5 inhibitors (PDE-5) have revolutionised the treatment of ED and are regarded as one of the most successful drug groups in modern medicine. Generally PDE-5 inhibitors are well tolerated and the incidence of side-effects is low, however a small percentage of individuals experience headache, flushing and abdominal discomfort, resulting in discontinuation of therapy. This has led to the development of second generation PDE-5 inhibitors, displaying more selectivity for the PDE-5 enzyme thereby reducing treatment interruption and improving compliance. Several other treatment modalities, including testosterone replacement therapy and prostaglandin administration are available for resistant or failed first-line treatment. This review provides an update on the current, and future, available drugs used in the management of ED. |
|---|